The Yale Cancer Center T-TARE Program provides support of up to $200,000 for groups of between three and five investigators headed by a member of the Cancer Center, for research with a significant translational or clinical component, with the express purpose of developing a multi-investigator grant submission to the National Cancer Institute, such as a Program Project Grant or SPORE grant.
Grant Review Process
The primary objectives of the T-TARE awards are to promote translational research and to facilitate collaborations between physicians and scientists. Consistent with these objectives, the review process of the proposals will be collaborative among physicians and scientists. Two individuals – one physician and one scientist – will be assigned to review two proposals and to score the merit of each proposal on a scale of 1 – 9 (1 = lowest/best score, 9 = highest/worst score) according to the criteria defined below. Following review and scoring, each review “team” will present a summary of the proposal and the results of the review to an executive committee, which will determine final funding decisions.
1. Potential for project developing into a multi-investigator grant proposal within one year
2. Translational potential (overall and within three year time period)
3. Scientific merit/clinical feasibility
4. Strength of collaborative team (scientific strength, successful funding/publication record, commitment to clinical investigation, prior evidence of team interaction)
5. Strength of senior leadership (funding/publication track record)
T-TARE Awarded to Head & Neck Cancers Program - July 1, 2016 - June 30, 2017
A new Translational Targeted Area of Research Excellence (T-TARE) grant has been awarded to the Head & Neck Cancers Program, led by Dr. Barbara Burtness and Dr. Wendell Yarbrough, to support their translational research efforts. Drs. Burtness and Yarbrough are actively working on a SPORE submission for Head and Neck Cancers to the NCI and the T-TARE grant funding will provide the resources needed to fund pilot projects and team science to strengthen their application. For more information about the T-TARE program, please contact Dr. Herbst or Ed Kaftan, PhD, Associate Director for Translational Research Administration.
2012 Award Recipients
Madhav Dhodapkar, MBBS
Targeting genetic instability towards personalized cancer prevention
Roy S. Herbst, MD, PhD
The biology and treatment of primary and metastatic lung cancer
Harriet Kluger, MD
Comprehensive approaches for understanding and treating melanoma brain metastases
W. Mark Saltzman, PhD and Joseph Piepmeier, MD
Translation of convection-enhanced delivery of drug-loaded nanoparticles for treatment of glioma
2013 Award Recipients
Next Generation Targeting of Oncogenes in the Tumor Microenvironment
Divide and Conquer: Advancing Therapy for Head and Neck Squamous Cell Carcinoma
Expanding Therapeutic Options for Triple Negative Breast Cancer
For more information on the T-TARE Awards, please contact Edward Kaftan, PhD.